Public Sector Pension Investment Board Buys 11,300 Shares of ANI Pharmaceuticals, Inc. $ANIP

Key Points

• The Public Sector Pension Investment Board increased its stake in ANI Pharmaceuticals by 27.3%, owning approximately $3.53 million worth of shares after acquiring an additional 11,300 shares during the first quarter.
• ANI Pharmaceuticals reported a quarterly earnings per share (EPS) of $1.80, surpassing estimates of $1.42, with revenue for the quarter rising 53.2% year-over-year to $211.37 million.
• Insider trading data shows that CEO Nikhil Lalwani sold 56,960 shares for nearly $4.9 million, reducing his ownership in the company by 12.17%.

Public Sector Pension Investment Board lifted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 27.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,668 shares of the specialty pharmaceutical company's stock after purchasing an additional 11,300 shares during the period. Public Sector Pension Investment Board owned approximately 0.24% of ANI Pharmaceuticals worth $3,526,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ANIP. National Bank of Canada FI acquired a new position in shares of ANI Pharmaceuticals during the first quarter worth approximately $79,000. GAMMA Investing LLC lifted its position in shares of ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after purchasing an additional 881 shares in the last quarter. Rafferty Asset Management LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $200,000. Bridgefront Capital LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $204,000. Finally, Mesirow Financial Investment Management Inc. acquired a new position in ANI Pharmaceuticals in the first quarter valued at approximately $206,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Trading Down 0.1%

NASDAQ:ANIP traded down $0.13 during trading hours on Friday, hitting $91.01. The stock had a trading volume of 432,200 shares, compared to its average volume of 738,532. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $92.53. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -118.19 and a beta of 0.61. The business's 50 day moving average is $70.63 and its 200-day moving average is $65.99.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same quarter in the prior year, the firm earned $1.02 earnings per share. The business's quarterly revenue was up 53.2% on a year-over-year basis. Sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 52,988 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $90.44, for a total value of $4,792,234.72. Following the completion of the sale, the chief operating officer owned 431,920 shares of the company's stock, valued at approximately $39,062,844.80. This represents a 10.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Antonio R. Pera sold 5,421 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $89.73, for a total transaction of $486,426.33. Following the completion of the sale, the director directly owned 29,952 shares of the company's stock, valued at $2,687,592.96. The trade was a 15.33% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 401,247 shares of company stock valued at $35,300,435. Corporate insiders own 12.70% of the company's stock.

Wall Street Analyst Weigh In

ANIP has been the topic of several analyst reports. Guggenheim restated a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Piper Sandler restated an "overweight" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. HC Wainwright restated a "buy" rating and issued a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Zacks Research upgraded shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday. Finally, Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a report on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $84.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.